BLK

Tyrosine-protein kinase Blk

98,267 patent compounds predicted against BLK, 78,413 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Linifanib (SCHEMBL93804)	1.00	6/20
SCHEMBL90887	0.49	6/20
SCHEMBL90935	0.49	6/20
SCHEMBL60289	0.48	5/20
SCHEMBL58735	0.47	5/20
SCHEMBL147422	0.66	4/20
SCHEMBL58313	0.59	4/20
SCHEMBL58543	0.57	4/20
SCHEMBL60464	0.57	4/20
SCHEMBL144979	0.56	4/20
SCHEMBL58550	0.55	4/20
SCHEMBL58416	0.50	4/20
SCHEMBL59547	0.49	4/20
SCHEMBL66159	0.49	4/20
SCHEMBL60366	0.45	4/20
SCHEMBL58496	0.44	4/20
SCHEMBL58420	0.43	4/20
SCHEMBL59205	0.42	4/20
SCHEMBL95142	1.00	3/20
SCHEMBL94964	0.79	3/20

Germline variants in BLK on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full BLK gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to BLK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers	PHASE3	UNKNOWN
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma	PHASE3	UNKNOWN
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.	PHASE1/PHASE2	UNKNOWN
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia	PHASE2	COMPLETED
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma	PHASE2	COMPLETED
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP	PHASE1/PHASE2	COMPLETED
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation	PHASE2	COMPLETED
A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus	PHASE1/PHASE2	RECRUITING
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL	PHASE2	RECRUITING
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia	PHASE2	ACTIVE_NOT_RECRUITING
CML Treated With Bosutinib After Relapse	PHASE2	COMPLETED
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia	PHASE1/PHASE2	WITHDRAWN
Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase	PHASE2	COMPLETED
Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL	PHASE1/PHASE2	UNKNOWN
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	ACTIVE_NOT_RECRUITING
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia	PHASE1	COMPLETED
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy	PHASE1	COMPLETED
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	PHASE1	COMPLETED
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a BLK binder may also engage these)

Protein	Name	Similarity
P00526	—	0.999	P00526 →
HCK	Tyrosine-protein kinase HCK	0.999	landscape →
P31693	—	0.999	P31693 →
Q6P6U0	—	0.998	Q6P6U0 →
Q6EWH2	—	0.998	Q6EWH2 →
P00524	—	0.997	P00524 →
Q1JPZ3	—	0.996	Q1JPZ3 →
Q01621	—	0.995	Q01621 →
Q95KR7	—	0.994	Q95KR7 →
P16277	—	0.994	P16277 →
A1Y2K1	—	0.993	A1Y2K1 →
P00523	—	0.993	P00523 →
FRK	Tyrosine-protein kinase FRK	0.993	landscape →
P27447	—	0.992	P27447 →
P50545	—	0.992	P50545 →
P00527	—	0.992	P00527 →
FGR	Tyrosine-protein kinase Fgr	0.992	landscape →
P63185	—	0.992	P63185 →
A0JNB0	—	0.992	A0JNB0 →
P13116	—	0.991	P13116 →
Q5PXS1	—	0.991	Q5PXS1 →
Q922K9	—	0.991	Q922K9 →
P13406	—	0.990	P13406 →
Q95M30	—	0.990	Q95M30 →
P27446	—	0.990	P27446 →
Q9WUD9	—	0.990	Q9WUD9 →
P10447	—	0.990	P10447 →
P06240	—	0.990	P06240 →
Q62844	—	0.990	Q62844 →
P09324	—	0.989	P09324 →